| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Urology [H. S., D. F., D. R. N., G. S. B., W. B. I.], Pathology [G. S. B.], Otolaryngology [K. O., P. C., D. S.], and Oncology [H. S., G. S. B., W. B. I.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-2411
The long arm of chromosome 10 is frequently affected by allelic loss in prostate cancer. PTEN/MMAC1, a candidate tumor suppressor gene located at 10q23.3, a region commonly deleted in prostate cancer, was recently identified and found to be deleted or mutated in cancer cell lines derived from a variety of human tissues including prostate. To examine the role of PTEN/MMAC1 in the progression of prostate cancer, we screened a unique set of 50 metastatic prostate cancer tissues from 19 cancer-death patients for alterations in the PTEN/MMAC1 gene, using single-strand conformational polymorphism analysis and direct sequencing to identify sequence changes and microsatellite analysis to examine allelic loss in the vicinity of PTEN/MMAC1. Overall, gene alterations (deletions or point mutations) were observed in at least 1 metastatic site in 12 of the 19 patients studied. Two cases had homozygous deletions that were confirmed by fluorescence in situ hybridization analysis. Four patients harbored point mutations, with one mutation being found in all four tumors (a primary lesion and three different metastases) from the same patient. The remaining three mutations were detected in only one of multiple metastases. Loss of heterozygosity was found in 10 of 18 informative cases, with 1 case showing a unique pattern of microsatellite instability in each of six different metastases examined. Loss of the same allele was found in all metastases in a given patient in 9 of 10 cases. These results indicate that PTEN/MMAC1 gene alterations occur frequently in lethal prostate cancer, although a substantial amount of mutational heterogeneity is found among different metastatic sites within the same patient. These latter findings emphasize the potentially complex genetic relationship that can exist between various clonal lineages of prostate cancer cells as they evolve during the metastatic process and suggest a molecular basis for phenotypic heterogeneity of different prostate cancer foci in patients with disseminated disease.
1 Supported by USPHS Grants CA58236, CA53258, CaPCURE, and American Foundation for Urologic Disease.
2 To whom requests for reprints should be addressed at Marburg 130b, Brady Urological Institute, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287. Phone: (410) 955-2518; Fax: (410) 955-0833; E-mail: wisaacs@welchlink.welch.jhu.edu.
Received 11/19/97. Accepted 12/10/97.
This article has been cited by other articles:
|
|
 |
|
  W. Zhang, J. Zhu, C. L. Efferson, C. Ware, J. Tammam, M. Angagaw, J. Laskey, K. A. Bettano, S. Kasibhatla, J. F. Reilly, et al. Inhibition of Tumor Growth Progression by Antiandrogens and mTOR Inhibitor in a Pten-Deficient Mouse Model of Prostate Cancer Cancer Res., September 15, 2009; 69(18): 7466 - 7472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Fernandez-Marcos, S. Abu-Baker, J. Joshi, A. Galvez, E. A. Castilla, M. Canamero, M. Collado, C. Saez, G. Moreno-Bueno, J. Palacios, et al. Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-{kappa}B activation and invasive prostate carcinoma PNAS, August 4, 2009; 106(31): 12962 - 12967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, S. Altuwaijri, F. Deng, L. Chen, P. Lal, U. K. Bhanot, R. Korets, S. Wenske, H. G. Lilja, C. Chang, et al. NF-{kappa}B Regulates Androgen Receptor Expression and Prostate Cancer Growth Am. J. Pathol., August 1, 2009; 175(2): 489 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sarker, A. H.M. Reid, T. A. Yap, and J. S. de Bono Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer Clin. Cancer Res., August 1, 2009; 15(15): 4799 - 4805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Blando, M. Portis, F. Benavides, A. Alexander, G. Mills, B. Dave, C. J. Conti, J. Kim, and C. L. Walker PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth Am. J. Pathol., May 1, 2009; 174(5): 1869 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. SUN, J. HUANG, T. HOMMA, D. KITA, H. KLOCKER, G. SCHAFER, P. BOYLE, and H. OHGAKI Genetic Alterations in the PI3K Pathway in Prostate Cancer Anticancer Res, May 1, 2009; 29(5): 1739 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A.T. Hildebrandt, H. Yang, M.-C. Hung, J. G. Izzo, M. Huang, J. Lin, J. A. Ajani, and X. Wu Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy J. Clin. Oncol., February 20, 2009; 27(6): 857 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hu, T. A. Dunn, S. Wei, S. Isharwal, R. W. Veltri, E. Humphreys, M. Han, A. W. Partin, R. L. Vessella, W. B. Isaacs, et al. Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer Cancer Res., January 1, 2009; 69(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Liu, S. Li, L. Gan, T. P. Kao, and H. Huang A Transcription-Independent Function of FOXO1 in Inhibition of Androgen-Independent Activation of the Androgen Receptor in Prostate Cancer Cells Cancer Res., December 15, 2008; 68(24): 10290 - 10299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Akakura, C. Huang, P. J. Nelson, B. Foster, and I. H. Gelman Loss of the ssecks/gravin/akap12 Gene Results in Prostatic Hyperplasia Cancer Res., July 1, 2008; 68(13): 5096 - 5103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zhu, C. X. Zhang, and H. B. Lieberman Rad9 Has a Functional Role in Human Prostate Carcinogenesis Cancer Res., March 1, 2008; 68(5): 1267 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hu, G.-x. Li, L. Wang, J. Watts, G. F. Combs Jr., and J. Lu Methylseleninic Acid Enhances Taxane Drug Efficacy against Human Prostate Cancer and Down-Regulates Antiapoptotic Proteins Bcl-XL and Survivin Clin. Cancer Res., February 15, 2008; 14(4): 1150 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z Wu, K. McRoberts, and D Theodorescu The role of PTEN in prostate cancer cell tropism to the bone micro-environment Carcinogenesis, July 1, 2007; 28(7): 1393 - 1400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Shaffer, M. A. Leversha, D. C. Danila, O. Lin, R. Gonzalez-Espinoza, B. Gu, A. Anand, K. Smith, P. Maslak, G. V. Doyle, et al. Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 2023 - 2029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, K. J. Bruxvoort, C. R. Zylstra, J. Liu, R. Cichowski, M.-C. Faugere, M. L. Bouxsein, C. Wan, B. O. Williams, and T. L. Clemens Lifelong accumulation of bone in mice lacking Pten in osteoblasts PNAS, February 13, 2007; 104(7): 2259 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cao, T. Subhawong, J. M. Albert, K. W. Kim, L. Geng, K. R. Sekhar, Y. J. Gi, and B. Lu Inhibition of Mammalian Target of Rapamycin or Apoptotic Pathway Induces Autophagy and Radiosensitizes PTEN Null Prostate Cancer Cells. Cancer Res., October 15, 2006; 66(20): 10040 - 10047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bertram, J. W. Peacock, C. Tan, A. L-F. Mui, S. W. Chung, M. E. Gleave, S. Dedhar, M. E. Cox, and C. J. Ong Inhibition of the Phosphatidylinositol 3'-Kinase Pathway Promotes Autocrine Fas-Induced Death of Phosphatase and Tensin Homologue-Deficient Prostate Cancer Cells. Cancer Res., May 1, 2006; 66(9): 4781 - 4788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. I. Yoo, D. W. Liu, S. L. Vu, R. T. Bronson, H. Wu, and J. Yuan Pten Deficiency Activates Distinct Downstream Signaling Pathways in a Tissue-Specific Manner Cancer Res., February 15, 2006; 66(4): 1929 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhong, G. Saribekyan, C.-P. Liao, M. B. Cohen, and P. Roy-Burman Cooperation between FGF8b Overexpression and PTEN Deficiency in Prostate Tumorigenesis Cancer Res., February 15, 2006; 66(4): 2188 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hill, Y. Song, R. D. Cardiff, and T. Van Dyke Heterogeneous Tumor Evolution Initiated by Loss of pRb Function in a Preclinical Prostate Cancer Model Cancer Res., November 15, 2005; 65(22): 10243 - 10254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ma, J. Teruya-Feldstein, N. Behrendt, Z. Chen, T. Noda, O. Hino, C. Cordon-Cardo, and P. P. Pandolfi Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression Genes & Dev., August 1, 2005; 19(15): 1779 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ma, A. C. Ziel-van der Made, B. Autar, H. A. van der Korput, M. Vermeij, P. van Duijn, K. B. Cleutjens, R. de Krijger, P. Krimpenfort, A. Berns, et al. Targeted Biallelic Inactivation of Pten in the Mouse Prostate Leads to Prostate Cancer Accompanied by Increased Epithelial Cell Proliferation but not by Reduced Apoptosis Cancer Res., July 1, 2005; 65(13): 5730 - 5739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary Molecular pathology of prostate cancer J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bandyopadhyay, S. K. Pai, S. Hirota, S. Hosobe, T. Tsukada, K. Miura, Y. Takano, K. Saito, T. Commes, D. Piquemal, et al. PTEN Up-Regulates the Tumor Metastasis Suppressor Gene Drg-1 in Prostate and Breast Cancer Cancer Res., November 1, 2004; 64(21): 7655 - 7660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Stern More than a Marker... Phosphorylated Akt in Prostate Carcinoma Clin. Cancer Res., October 1, 2004; 10(19): 6407 - 6410. [Full Text] [PDF]
|
|
|
|
|
|
I. Sansal and W. R. Sellers The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway J. Clin. Oncol., July 15, 2004; 22(14): 2954 - 2963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Nelson, A. M. De Marzo, and W. B. Isaacs Prostate Cancer N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381. [Full Text] [PDF]
|
|
|
|
|
|
G. Narla, S. L. Friedman, and J. A. Martignetti Kruppel Cripples Prostate Cancer: KLF6 Progress and Prospects Am. J. Pathol., April 1, 2003; 162(4): 1047 - 1052. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Davies, S. J. Kim, N. U. Parikh, Z. Dong, C. D. Bucana, and G. E. Gallick Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Clin. Cancer Res., June 1, 2002; 8(6): 1904 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ichinose, X.-H. Liu, N. Hagihara, and R. J. Youle Extracellular Bad Fused to Toxin Transport Domains Induces Apoptosis Cancer Res., March 1, 2002; 62(5): 1433 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dicuonzo, S. Angeletti, J. Garcia-Foncillas, A. Brugarolas, Y. Okrouzhnov, D. Santini, G. Tonini, G. Lorino, M. De Cesaris, and A. Baldi Colorectal Carcinomas and PTEN/MMAC1 Gene Mutations Clin. Cancer Res., December 1, 2001; 7(12): 4049 - 4053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Grossmann, H. Huang, and D. J. Tindall Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer J Natl Cancer Inst, November 21, 2001; 93(22): 1687 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Huang, J. C. Cheville, Y. Pan, P. C. Roche, L. J. Schmidt, and D. J. Tindall PTEN Induces Chemosensitivity in PTEN-mutated Prostate Cancer Cells by Suppression of Bcl-2 Expression J. Biol. Chem., October 12, 2001; 276(42): 38830 - 38836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kwabi-Addo, D. Giri, K. Schmidt, K. Podsypanina, R. Parsons, N. Greenberg, and M. Ittmann Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression PNAS, September 5, 2001; (2001) 201167798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-T. Dong, C.-L. Li, T. W. Sipe, and H. F. Frierson Jr. Mutations of PTEN/MMAC1 in Primary Prostate Cancers from Chinese Patients Clin. Cancer Res., February 1, 2001; 7(2): 304 - 308. [Abstract] [Full Text]
|
|
|
|
|
|
C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]
|
|
|
|
 |
|
 J. T. Çelebi, I. Shendrik, D. N Silvers, and M. Peacocke Identification of PTEN mutations in metastatic melanoma specimens J. Med. Genet., September 1, 2000; 37(9): 653 - 657. [Abstract] [Full Text]
|
|
|
|
|
|
A. Schneider, S. Borgnat, H. Lang, O. Régine, V. Lindner, M. Kassem, C. Saussine, P. Oudet, D. Jacqmin, and M. P. Gaub Evaluation of Microsatellite Analysis in Urine Sediment for Diagnosis of Bladder Cancer Cancer Res., August 1, 2000; 60(16): 4617 - 4622. [Abstract] [Full Text]
|
|
|
|
|
|
H. Zhong, K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M.-M. Georgescu, J. W. Simons, and G. L. Semenza Modulation of Hypoxia-inducible Factor 1{{alpha}} Expression by the Epidermal Growth Factor/Phosphatidylinositol 3-Kinase/PTEN/AKT/FRAP Pathway in Human Prostate Cancer Cells: Implications for Tumor Angiogenesis and Therapeutics Cancer Res., March 1, 2000; 60(6): 1541 - 1545. [Abstract] [Full Text]
|
|
|
|
|
|
D. I. Quinn, S. M. Henshall, D. R. Head, D. Golovsky, J. D. Wilson, P. C. Brenner, J. J. Turner, W. Delprado, J. F. Finlayson, P. D. Stricker, et al. Prognostic Significance of p53 Nuclear Accumulation in Localized Prostate Cancer Treated with Radical Prostatectomy Cancer Res., March 1, 2000; 60(6): 1585 - 1594. [Abstract] [Full Text]
|
|
|
|
|
|
I. U. Ali, L. M. Schriml, and M. Dean Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity J Natl Cancer Inst, November 17, 1999; 91(22): 1922 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tamura, J. Gu, H. Tran, and K. M. Yamada PTEN Gene and Integrin Signaling in Cancer J Natl Cancer Inst, November 3, 1999; 91(21): 1820 - 1828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. McMenamin, P. Soung, S. Perera, I. Kaplan, M. Loda, and W. R. Sellers Loss of PTEN Expression in Paraffin-embedded Primary Prostate Cancer Correlates with High Gleason Score and Advanced Stage Cancer Res., September 1, 1999; 59(17): 4291 - 4296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hahn, I. Wieland, O. N. Koufaki, H. Gorgens, S. B. Sobottka, G. Schackert, and H. K. Schackert Genetic Alterations of the Tumor Suppressor Gene PTEN/MMAC1 in Human Brain Metastases Clin. Cancer Res., September 1, 1999; 5(9): 2431 - 2437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Davies, D. Koul, H. Dhesi, R. Berman, T. J. McDonnell, D. McConkey, W. K. A. Yung, and P. A. Steck Regulation of Akt/PKB Activity, Cellular Growth, and Apoptosis in Prostate Carcinoma Cells by MMAC/PTEN Cancer Res., June 1, 1999; 59(11): 2551 - 2556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Cantley and B. G. Neel New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway PNAS, April 13, 1999; 96(8): 4240 - 4245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken Molecular Genetics and Epidemiology of Prostate Carcinoma Endocr. Rev., February 1, 1999; 20(1): 22 - 45. [Abstract] [Full Text]
|
|
|
|
|
|
M. Tamura, J. Gu, T. Takino, and K. M. Yamada Tumor Suppressor PTEN Inhibition of Cell Invasion, Migration, and Growth: Differential Involvement of Focal Adhesion Kinase and p130Cas Cancer Res., January 1, 1999; 59(2): 442 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lichy, M. Zavar, M. M. Tsai, T. J. O'Leary, and J. K. Taubenberger Loss of Heterozygosity on Chromosome 11p15 during Histological Progression in Microdissected Ductal Carcinoma of the Breast Am. J. Pathol., July 1, 1998; 153(1): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. E. Whang, X. Wu, H. Suzuki, R. E. Reiter, C. Tran, R. L. Vessella, J. W. Said, W. B. Isaacs, and C. L. Sawyers Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression PNAS, April 28, 1998; 95(9): 5246 - 5250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kwabi-Addo, D. Giri, K. Schmidt, K. Podsypanina, R. Parsons, N. Greenberg, and M. Ittmann Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression PNAS, September 25, 2001; 98(20): 11563 - 11568. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
